A Study of the Treatment of Postmenopausal Women With Osteoporosis
NCT00543023
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
104
Enrollment
INDUSTRY
Sponsor class
Conditions
Osteoporosis, Post-Menopausal
Interventions
DRUG:
teriparatide 20 micrograms/day subcutaneous
DRUG:
salmon calcitonin 100 IU/day subcutaneous
Sponsor
Eli Lilly and Company